✦ LIBER ✦

Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: A Gynecologic Oncology Group study

✍ Scribed by Abdulhay, Gazi; DiSaia, Philip J.; Blessing, John A.; Creasman, William T.

Book ID: 123533438
Publisher: Elsevier Science
Year: 1985
Tongue: English
Weight: 650 KB
Volume: 152
Category: Article
ISSN: 1097-6868
DOI: 10.1016/S0002-9378(85)80151-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I study of paclitaxel, topotecan

A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: A Gynecologic Oncology Group study

✍ Deborah K. Armstrong; Michael A. Bookman; William McGuire; Robert E. Bristow; Je 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 108 KB

Co-expression of angiogenic markers and

Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: A Gynecologic Oncology Group study

✍ Angeles Alvarez Secord; Kathleen M. Darcy; Alan Hutson; Paula S. Lee; Laura J. H 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 603 KB

Phase II trial of galactitol 1,2:5,6-dia

Phase II trial of galactitol 1,2:5,6-dianhydro (NSC 132313) in the treatment of advanced gynecologic malignancies: A gynecologic oncology group study

✍ Frederick B. Stehman; Johannes Blom; John A. Blessing; Clarence E. Ehrlich; Char 📂 Article 📅 1983 🏛 Elsevier Science 🌐 English ⚖ 641 KB

CA-125 change after chemotherapy in pred

CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers : A Gynecologic Oncology Group study

✍ Chunqiao Tian; Maurie Markman; Richard Zaino; Robert F. Ozols; William P. McGuir 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB 👁 2 views

Phase II study of esorubicin (4′-deozydo

Phase II study of esorubicin (4′-deozydoxorubicin) in advanced epithelial carcinoma of the ovary:A Gynecologic Oncology Group study

✍ William P. McGuire; John A. Blessing; Michael L. Berman 📂 Article 📅 1989 🏛 Springer US 🌐 English ⚖ 275 KB

Twenty-six patients with advanced, measurable epithelial carcinoma of the ovary were treated with 76 courses of esorubicin at doses ranging from 20-30 mg/m2 every 3 weeks. All patients are evaluable for toxicity and response. All patients had received prior therapy including radiation therapy in 9,

A phase II study of vorinostat in the tr

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study

✍ Susan C. Modesitt; Michael Sill; James S. Hoffman; David P. Bender 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 251 KB